Recently, Mengniu Ruibuen officially launched its inaugural human milk oligosaccharide (HMO) formula milk powder—Ruibuen Enzhi Stage 4—injecting fresh vitalitythe infant nutrition sector.
This innovative product incorporates Synaura™ HMO, a human milk oligosaccharide independently developed by Synaura Biotech. This ingredient received approval from China's National Health Commission on 7 October 2023, making Synaura Biotech the sole domestic Chinese enterprise among the first batch of approved companies. This milestone achievement not only underscores Synaura Biotech's leading position in the field of ‘domestic independent research and development,’ but also demonstrates its outstanding contributions to technological innovation in infant nutrition.
Breaking Through Industrial Barriers Through Independent R&D
Human milk oligosaccharides (HMOs) constitute the third most abundant solid component in breast milk after lactose and fat, playing a crucial role in promoting immune regulation, cognitive development, and gut health in infants and young children. The health benefits of HMOs have been substantiated by numerous fundamental and clinical studies, with their significance for infant growth and development now widely recognised within the industry.
Aware of HMOs' pivotal role, global infant formula giants have long pursued intensive research. For years, industrial-scale HMO production technology remained firmly in the hands of Western conglomerates, creating a critical bottleneck that stifled China's domestic HMO raw material development and production. This constraint has also hampered the high-quality advancement of China's dairy industry. Against this backdrop, Synaura Biotech's breakthrough innovation proves particularly significant and encouraging. The phrase ‘domestically developed’ carries substantial weight in Synaura's case, as the industrial application of HMOs propels China's dairy sector forward on its path towards high-quality development.
Rigorous refinement for exceptional performance
Synaura Biotech's strengths in HMO research extend beyond domestic R&D capabilities to industry-leading product performance. Laboratory data demonstrates that Synaura's proprietary HMOs achieve high purity, minimal impurities and odourlessness. This data not only validates the high standards and exceptional performance of Synaura's independently developed HMOs, but also provides robust quality assurance for domestic dairy products, driving the industry towards higher quality standards.
The Five Key Advantages of Synaura™ HMO
Continuously Empowering Cutting-Edge Breakthroughs
Tracking the industry's developmental trajectory, China's infant formula sector has progressed from an initial phase of balanced supplementation with fundamental nutrients (such as proteins, fats, carbohydrates, vitamins, and minerals), through an enhancement stage featuring representative nutrients like DHA, lactoferrin, and OPO, to its current comprehensive adoption of HMO technology.
Through the continuous advancement and collective efforts of Chinese biotechnology companies like Synaura Biotech, more innovations and scientific discoveries will be translatedpractical applications, propelling China's infant formula industry towards a path of high-quality development.
